ReviewWorld journal of hepatology2015
Micro RNAs in the development of non-alcoholic fatty liver disease.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Trial
- Elevated mir-141 in obesity: Insights into the interplay with sirtuin 1 and non-alcoholic fatty liver disease.Obesity science & practice · 2024Article
- Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model.Lipids in health and disease · 2024Article
- Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis.Vascular pharmacology · 2024Review
- Time for micro-RNAs in steatotic liver disease: a case-control study.Frontiers in endocrinology · 2024Article
- Review
- Review
- SIRT1: A promising therapeutic target for chronic pain.CNS neuroscience & therapeutics · 2022Review
- CirculatoryGenes · 2021Article
- Clinical Significance of HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 RNA Panel in NAFLD/NASH Diagnosis: Egyptian Pilot Study.Biomedicines · 2021Article
- The relationship between polyphenols and miRNAs: A novel therapeutic strategy for metabolic associated fatty liver disease.Hepatology forum · 2021Review
- mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2021Article
- Effect of Chronic Western Diets on Non-Alcoholic Fatty Liver of Male Mice Modifying the PPAR-γ Pathway via miR-27b-5p Regulation.International journal of molecular sciences · 2021Article
- Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment.Frontiers in cardiovascular medicine · 2021Review
- Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis.Frontiers in cell and developmental biology · 2021Article
- Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.Pharmaceutical medicine · 2019Review
- Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease.Frontiers in physiology · 2019Review
- New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.Hepatobiliary surgery and nutrition · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease or nonalcoholic fatty liver disease (NAFLD) refers to a group of disorders that arise from the accrual of fat in hepatocytes. Although various factors have been associated with the development of NAFLD, including genetic predisposition and environmental exposures, little is known about the underlying pathogenesis of the disease. Research efforts are ongoing to identify biological targets and signaling pathways that mediate NAFLD. Emerging evidence has implicated a role for micro RNAs (miRNAs), short single-stranded molecules that regulate gene expression either transcriptionally, through targeting of promoter regions, or post-transcriptionally, by blocking translation or promoting cleavage of specific target mRNAs. Several miRNAs have been associated with NAFLD, although our understanding of the biology underlying their role is still emerging. The goal of this review is to present an overview of the current state of knowledge of miRNAs involved in the development of NAFLD across a range of in vitro and in vivo models, including miRNAs that contribute to pathological mechanisms related to fatty liver in humans. Much less is known about the specific targets of miRNAs in cells, nor the molecular mechanisms involved in the development and progression NAFLD and related outcomes. More recently, the identification and validation of miRNA signatures in serum may facilitate the development of improved methods for diagnosis and clinical monitoring of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.